These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16984325)

  • 1. Analysis of a partially observed binary covariate process and a censored failure time in the presence of truncation and competing risks.
    Tian L; Lagakos S
    Biometrics; 2006 Sep; 62(3):821-8. PubMed ID: 16984325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A joint model for survival and longitudinal data measured with error.
    Wulfsohn MS; Tsiatis AA
    Biometrics; 1997 Mar; 53(1):330-9. PubMed ID: 9147598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covariate analysis of competing-risks data with log-linear models.
    Larson MG
    Biometrics; 1984 Jun; 40(2):459-69. PubMed ID: 6487729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-dependent covariates in the proportional subdistribution hazards model for competing risks.
    Beyersmann J; Schumacher M
    Biostatistics; 2008 Oct; 9(4):765-76. PubMed ID: 18434297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating equations with incomplete categorical covariates in the Cox model.
    Lipsitz SR; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):1002-13. PubMed ID: 9750248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A competing risks analysis of presenting AIDS diagnoses trends.
    Fusaro RE; Bacchetti P; Jewell NP
    Biometrics; 1996 Mar; 52(1):211-25. PubMed ID: 8934593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partly conditional survival models for longitudinal data.
    Zheng Y; Heagerty PJ
    Biometrics; 2005 Jun; 61(2):379-91. PubMed ID: 16011684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Markov chain Monte Carlo EM algorithm for analyzing interval-censored data under the Cox proportional hazards model.
    Goggins WB; Finkelstein DM; Schoenfeld DA; Zaslavsky AM
    Biometrics; 1998 Dec; 54(4):1498-507. PubMed ID: 9883548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma.
    Geier A; Gartung C; Dietrich CG
    N Engl J Med; 2002 Nov; 347(21):1721-2; author reply 1721-2. PubMed ID: 12444194
    [No Abstract]   [Full Text] [Related]  

  • 10. Proportional hazards regression for cancer studies.
    Ghosh D
    Biometrics; 2008 Mar; 64(1):141-8. PubMed ID: 17573863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
    Geskus RB
    Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression analysis of doubly censored failure time data with frailty.
    Kim YJ
    Biometrics; 2006 Jun; 62(2):458-64. PubMed ID: 16918909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A shared random effects model for censored medical costs and mortality.
    Liu L; Wolfe RA; Kalbfleisch JD
    Stat Med; 2007 Jan; 26(1):139-55. PubMed ID: 16526006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple augmentation for interval-censored data with measurement error.
    Song X; Ma S
    Stat Med; 2008 Jul; 27(16):3178-90. PubMed ID: 18040984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simulating competing risks data in survival analysis.
    Beyersmann J; Latouche A; Buchholz A; Schumacher M
    Stat Med; 2009 Mar; 28(6):956-71. PubMed ID: 19125387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
    Fwu CW; Chien YC; Kirk GD; Nelson KE; You SL; Kuo HS; Feinleib M; Chen CJ
    J Natl Cancer Inst; 2009 Jul; 101(14):1019-27. PubMed ID: 19535774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semiparametric analysis of survival data with left truncation and dependent right censoring.
    Jiang H; Fine JP; Chappell R
    Biometrics; 2005 Jun; 61(2):567-75. PubMed ID: 16011706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
    Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
    J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local full likelihood estimation for the proportional hazards model.
    Gentleman R; Crowley J
    Biometrics; 1991 Dec; 47(4):1283-96. PubMed ID: 1786319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cure rate model with interval censored data.
    Kim YJ; Jhun M
    Stat Med; 2008 Jan; 27(1):3-14. PubMed ID: 17516589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.